Catalyst
Slingshot members are tracking this event:
Olumacostat glasaretil CLAREOS-1 Phase 3 clinical trial topline results in patients with acne vulgaris expected in the first half of 2018 -Did Not Meet Co-Primary Endpoints, Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DERM |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 05, 2018
Occurred Source:
http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2336111
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Olumacostat Glasaretil, Clareos-1, Phase 3
